Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction - ScienceDirect
NSAIDS and Cardiovascular Risk - Sports Medicine Review
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Diclofenac significantly increases cardiovascular risk, large study suggests | MIMS online
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs - The Lancet
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Cardiovascular risk associated with non-steroidal anti-inflammatory... | Download Scientific Diagram
Ibuprofen and cardiovascular safety
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Eric Topol on X: "Bad news on diclofenac (Voltaren), a commonly used anti-inflammatory, with heart risks in excess of acetaminophen, naproxen and ibuprofen https://t.co/pXNzV5vCv4 @bmj_latest open-access by @Morten__Schmidt @ToftSorensen @Lars_HP ...
Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis - Scholle - 2020 - Journal of Internal Medicine - Wiley Online Library
Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease | Circulation: Cardiovascular Quality and Outcomes
Diclofenac Linked to Increased Cardiovascular Health Risks | Sci.News
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials | SpringerLink
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update | SpringerLink
Diclofenac (Voltaren) and risk of cardiovascular events (heart attack and stroke)